看片视频

Object moved to here.

看片视频 :: Pilot & Feasibility Program Application

看片视频


Adipose-derived MSCs Treatment of Diabetes and Diabetic Bladder Dysfunction
Summary Data Summary
Applicant Liu, Guiming
E-Mail Address gxl148@case.edu
Project Title Adipose-derived MSCs Treatment of Diabetes and Diabetic Bladder Dysfunction
CBU ID 12GHSU184
External SubContract ID 25732-6
Diabetic Complication Uropathy
Funding Program Group Pilot & Feasibility [PF2012]
Abstract The overall goals of this application are to examine the time-dependence and
potential mechanisms of action of adipose-derived mesenchymal stem cells (aMSCs)
in the treatment of diabetes mellitus and diabetic bladder dysfunction (DBD).
Novel treatments are required for DBD, one of the most common, costly, and yet
understudied complications of diabetes. Based on published research and our
preliminary data, we
hypothesize that administration of aMSCs can reverse the hyperglycemia in
streptozotocin-induced type 1 diabetes in a time-dependent manner, having an
effect when sufficient insulin-producing cells still remain, but not after
long-term, sustained damage. Moreover, we hypothesize that aMSCs can improve DBD
to some extent even when the hyperglycemia is not reversed. We further
hypothesize that therapeutic effects of aMSCs can be exerted via a
paracrine-mediated mechanism, and that administration of conditioned mediumfrom
aMSCs can reverse or improve hyperglycemia and DBD. Finally, we hypothesize that
culturing aMSCs
with serum from diabetic rats will enhance the therapeutic benefit of the CM
compared with culturing aMSCswith regular serum, due to the presence of 鈥渢issue
damage-related鈥 factors in diabetic rat serum that will stimulate aMSCs to
secrete specific 鈥渢issue repair鈥 factors. Through the Diabetic Complications
ConsortiumPilot & Feasibility funding mechanism we propose to test those
hypotheses by conducting the following Specific Aims: 1) To examine the effects
of aMSCs on hyperglycemia reversal and DBD at different diabetesstages in
STZ-induced diabetic rats. 2) To compare the effects of administration of aMSCs
vs. conditioned medium from aMSCs cultured with standard fetal bovine serum,
normal rat serum, or diabetic rat serum, onhyperglycemia and DBD in STZ-induced
diabetic rats. The results of this study will provide important insights into a
potential new therapy for patients with DBD.
RELEVANCE
Application PDF Application Research Plan
Status Contract Executed
Key Personnel
Salary Total Costs 33194
Supply Total Costs 30500
Equipment Total Costs 0
Travel/Other Total Costs 0
Direct Costs 63694
Indirect Costs Proposed 36306
Total Costs Proposed 100000
Total Costs Approved 100000
Start Date 10/1/2012
End Date 9/30/2013
IFO Name Bissell, Robin
IFO E-Mail Address medres@case.edu
IACUC/IRB No. 2009-0103
IACUC/IRB Institution Case Western Reserve
Entity ID No. 34-1018992
Report Request Date 10/30/2013
T1D NO
TypeCount
Invoices 5
Progress Reports 1
Data Submission


Invoices
UrlCBU IDExternal IDInstitutionDateDirectIndirectInvoiceBalancePDF
  View  12GHSU18425732-6Case Western Reserve7/30/2013$15,638.71$8,914.07$24,552.78-View PDF
  View  12GHSU18425732-6Case Western Reserve4/29/2014$9,332.71-$9,332.71-View PDF
  View  12GHSU18425732-6Case Western Reserve4/28/2013$10,865.00$6,193.05$17,058.05-View PDF
  View  12GHSU18425732-6Case Western Reserve10/14/2013$19,086.26$10,879.17$29,965.43-View PDF
  View  12GHSU18425732-6Case Western Reserve1/13/2014$12,159.90$6,931.13$19,091.03-View PDF


Reports
Click here to cancel and return to funding program application

*Author:
*SubContract:
*Select File:

Click browse and select the file to upload.
(Please upload ONLY TXT, Image Files (not histolgy), PDF, XLS, XLSX, DOC, or DOCX files.)